The use of 3-D mammography to complement a standard 2-D approach in breast cancer screening is becoming more standard. But all previous FDA approvals of mammography systems have included a combination of both 3-D and 2-D approaches. Now, Siemens has nabbed the first FDA approval for a 3-D digital breast tomosynthesis system.
New data indicates that 3-D mammography (or tomosynthesis), when added to standard digital mammography, can result in fewer patients being recalled for follow-up and more accurate cancer diagnosis.
The American Cancer Society has partnered with Samsung and software startup Breezie to conduct a pilot program to offer breast cancer patients a single point of contact across their medical team, family and caregivers as well as to offer access to customized treatment and clinical trial information and an online support group.
Saudi Arabian researchers are deploying single-walled carbon nanotubes as drug delivery agents in the fight against breast cancer.
The interaction between breast cancer cells and a receptor protein called EPHA2 helps explain how the cancer spreads through the body, according to a prominent group of investigators looking for new ways to fight cancer.
Pfizer's Ibrance has been steamrolling since it nabbed an early FDA go-ahead last February. And even with competition coming up the pipeline from the company's Big Pharma rivals, Pfizer intends to keep it that way.
Research coming from the Fred Hutchinson Cancer Research Center and Johns Hopkins Medical Institute concludes that the deadly spreading of cancer occurs in clusters rather than single cancer cells.
Seno Medical hopes that its opto-acoustic breast cancer screener will be used to make it easier for physicians to identify benign masses than traditional ultrasound methods alone. In practice, this could help limit the need for biopsy to determine cancerous masses.
Backers of Israeli startup Vayyar Imaging do not have modest ambitions. They expect that the company's technology could revolutionize cancer detection and easily enable remote vital sign tracking--all that based on the company's 3-D imaging sensor technology that's touted as "making it possible to see through objects."
Novian Health is trumpeting promising results from a study of its innovative laser ablation treatment for breast cancer, putting wind in the company's sails as it eyes FDA approval for its device.